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SchizophreniaIntroduction: Schizophrenia affects between 0.3% and 2% of theworldwide population. A genetic contribution has
been postulated in the development of this disorder. Genes such as ApoE have been implicated in the
neurodevelopment associated with schizophrenia in case–control and meta-analysis studies, but the results re-
main inconclusive. Due to this, the aim of the present study was to explore the association between ApoE and
schizophrenia through a meta-analysis.
Material and methods:We collected all relevant studies by searching PubMed and EBSCO databases. The pooled
odds ratios with 95% conﬁdence intervals were calculated to estimate the association. The following models
were evaluated: A) ε4 vs ε3, B) ε4 vs ε2, C) ε4 vs ε3+ ε2, D) Caucasian population and E) Asian population. Sta-
tistical analyses were performed using EPIDAT 3.1 software.
Results: The meta-analyses comprised 28 association studies, which included 4703 controls and 3452 subjects
with schizophrenia. A signiﬁcant protective effect was found for allele ε3 in the Asian population (OR = 0.73,
95% CI = 0.54–0.98). No signiﬁcant associations were observed in the other models and populations analyzed.
Conclusions:Ourmeta-analysis suggests a protective association betweenApoE allele ε3 and schizophrenia in the
Asian population.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Schizophrenia is a complex genetic disorder which may involve
multiple small-effect genes (Chen et al., 1999, 2015; Fernández et al.,
1999; Joober et al., 1996; Thibaut et al., 1999; Tovilla-Zárate et al.,
2013). In this regard, apolipoprotein E (ApoE) is a genemost commonly
associated in theﬁeld of global genetic analysiswith the identiﬁcation of
markers that may help with the diagnosis of the disease or with some
indication concerning this pathology (Harrington et al., 1995; Liutónoma de Tabasco, División
Sur, Cuarta Sección, C.P. 86650
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in.hdez.diaz@gmail.com
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illo),
inmegen.gob.mx (A. Genis),
rado).
This is an open access article under thet al., 2003; Sorbi et al., 1998; Tovilla-Zárate et al., 2009). ApoE is a
lipid transport associated protein of 34 kD; it is the product of a single
gene located at chromosome 19q13.2 locus. This protein codes for 3
common isoforms: ε2, ε3 and ε4 (Durany et al., 2000; Kampman et al.,
2004; Kimura et al., 2000; Vila-Rodríguez et al., 2011), due to
cysteine-arginine interchanges at residue 112. These changes in amino
acids result from two single nucleotide polymorphisms of the ApoE
gene at nucleotides 334 and 472 (Igata-Yi et al., 1997; Martorell et al.,
2001; Saiz et al., 2002; Zhu et al., 1996). Furthermore, these 2 polymor-
phisms induce complex biological functions which may precipitate the
symptoms of psychiatric illnesses (Kecmanovic et al., 2010; Lan et al.,
1997; Lee et al., 2001; Moberg et al., 2006). The study of the ApoE
gene and schizophrenia started with the study of Harrington et al.
(1995) in which the authors reported that the frequency of allele ε4
was associated with schizophrenia. Subsequently, further studies re-
vealed possible effects of this gene on clinical variables of the illness
(Arnold et al., 1997; Dean et al., 2003; Kimura et al., 1997). However,
these ﬁndings have been challenged by studies that have failed toe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Methodological quality of ApoE gene variant of study association included based on the
Newcastle–Ottawa scale.
Reference Selection Comparability Exposure Total score
Harrington et al. (1995) ☆☆☆ ☆ ☆☆ 6
Joober et al. (1996) ☆☆ ☆ ☆☆☆ 6
Jonsson et al. (1996) ☆☆☆ ☆☆ ☆☆☆ 7
Zhu et al. (1996) ☆☆☆ ☆ ☆☆ 6
Igata-Yi et al. (1997) ☆☆ ☆ ☆☆☆ 6
Kimura et al. (1997) ☆☆☆ ☆ ☆☆ 6
Lan et al. (1997) ☆☆☆ ☆ ☆☆☆ 7
Town et al. (1997) ☆☆☆ ☆ ☆☆☆ 7
Arnold et al. (1997) ☆☆☆ ☆ ☆☆ 6
Thibaut et al. (1998) ☆☆ ☆ ☆☆☆ 6
Sorbi et al. (1998) ☆☆ ☆☆ ☆☆ 6
Fernández et al. (1999) ☆☆ ☆ ☆☆☆ 6
Chen et al. (1999) ☆☆☆ ☆ ☆☆ 6
Thibaut et al. (1999) ☆☆☆ ☆ ☆☆☆ 7
Durany et al. (2000) ☆☆☆ ☆ ☆☆☆ 7
Kimura et al. (2000) ☆☆ ☆☆ ☆☆ 6
Martorell et al. (2001) ☆☆ ☆ ☆☆☆ 6
Lee et al. (2001) ☆☆☆ ☆ ☆☆☆ 7
Saiz et al. (2002) ☆☆☆ ☆ ☆☆☆ 7
Schurhoff et al. (2003) ☆☆☆ ☆ ☆☆☆ 7
Liu et al. (2003) ☆☆ ☆ ☆☆☆ 6
Dean et al. (2003) ☆☆☆ ☆ ☆☆☆ 7
Kampman et al. (2004) ☆☆ ☆ ☆☆☆ 6
Moberg et al. (2006) ☆☆☆ ☆ ☆☆ 6
Akanji et al. (2009) ☆☆☆ ☆ ☆☆ 6
Tovilla-Zárate et al. (2009) ☆☆☆ ☆ ☆☆☆ 7
Kecmanovic et al. (2010) ☆☆ ☆ ☆☆☆ 6
Vila-Rodríguez et al. (2011) ☆☆☆ ☆ ☆☆ 6
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(Akanji et al., 2009; Chee and Salina, 2014; Chen et al., 2015; Jonsson
et al., 1996; Schurhoff et al., 2003; Thibaut et al., 1998; Town et al.,
1997). Despite these extensive studies concerning ApoE gene and
schizophrenia, the association between them remains unclear. To ad-
dress this problem, our aimwas to perform ameta-analysis and system-
atic review inwhichwe collected and catalogued all genetic association
studies published in the ﬁeld of schizophrenia and ApoE to investigate
whether a genetic risk factor could be associated with the development
of the disease.
2. Methods
2.1. Systematic review and meta-analysis
The systematic review and meta-analysis complied with the Pre-
ferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) criteria (Moher et al., 2009; Swartz, 2011).
2.2. Identiﬁcation and selection of publications
To identify studies eligible for meta-analysis and systematic review
we surveyed PubMed and EBSCO databases. The reports were searched
with the keywords “ApoE and schizophrenia”. Also, these keywords
were employed to ﬁnd summaries. In addition, studies had to meet
the following criteria: (1) to be published in peer-reviewed journals;
(2) to present original data on ApoE genotype frequencies in patients
with schizophrenia (3) to contain independent data from other studies;
(4) to be case–control studies; (5) to use healthy subjects as controls
and schizophrenics as patients, and (6) to be written in English.
Inclusion criteria were determined by two researchers (TBGC and
YHD), working independently. When the researchers were in disagree-
ment a third researcher (CATZ) was consulted.
2.3. Data extraction
For the systematic review, after relevant studies were identiﬁed,
data extraction was carried out by the same two researchers working
independently, though in the end a consensus was reached. From the
included studies the following data were extracted and analyzed: au-
thors, year of publication, region, ethnical origin, sample size, number
of cases and controls, gender, age, psychiatric diagnosis and genotype
and allele frequencies.
The meta-analysis was constructed based on 4 categories: (1) ex-
posed sick, (2) exposed not sick, (3) not exposed sick, and (4) not
exposed not sick. The term “sick” stands for schizophrenia patients
and the term “exposed” refers to the risk allele.
2.4. Data analysis
For the systematic review andmeta-analysis the studies deemed for
inclusion were scored using the Newcastle–Ottawa Assessment Scale
(NOS) (Table 1). A score of 6 was considered the cut-off point for high
quality. To give more support to our analysis, we also considered the
Grading of Recommendations Assessment, Development and Evalua-
tion Scale (GRADES) procedures (http://www.gradeworkinggroup.
org; Table 2).
The meta-analysis was performed using the EPIDAT 3.1 program
(Software for Epidemiologic Analysis of Tabulated Data; http://dxsp.
sergas.es). In all the analyses we used the random effects model as pre-
viously reported (González-Castro et al., 2013a,b, 2014a,b). Initially, we
measured the heterogeneity of the sample using the Dersimonian and
Laird Q test supported by graphs to help with the visualization of
the studies that affected heterogeneity. We presented the outcomes
expressed as odds ratios (ORs). For the ApoE gene, ORs were calculated
for each model used, viz.: ε4 vs ε3, ε4 vs ε2, and ε4 carriers vs ε3 + ε2non-carriers. To address publication bias we used Egger's test and funnel
plots in the same software. We performed a sensitivity analysis and the
inﬂuence of each study on global estimation was analyzed and graphed.
Also, we used the Pearson's χ2 test to measure the Hardy–Weinberg
equilibrium and genotype distribution to assess goodness of ﬁt.
3. Results
3.1. Description of the studies
The search strategy retrieved 188 potentially relevant studies, but
after discarding duplicates and not valuable data according to the inclu-
sion criteria, 28 reports remained for the analysis (Akanji et al., 2009;
Arnold et al., 1997; Chen et al., 1999; Dean et al., 2003; Durany et al.,
2000; Fernández et al., 1999; Harrington et al., 1995; Igata-Yi et al.,
1997; Jonsson et al., 1996; Joober et al., 1996; Kampman et al., 2004;
Kecmanovic et al., 2010; Kimura et al., 1997, 2000; Lan et al., 1997;
Lee et al., 2001; Liu et al., 2003; Martorell et al., 2001; Moberg et al.,
2006; Saiz et al., 2002; Schurhoff et al., 2003; Sorbi et al., 1998; Thibaut
et al., 1998, 1999; Tovilla-Zárate et al., 2009; Town et al., 1997;
Vila-Rodríguez et al., 2011; Zhu et al., 1996). Fig. 1 shows the ﬂow-
chart illustrating the selection of the studies. In addition, the articles in-
cluded in this analysis are shown in Fig. 2 by year of publication. From
these 28 reports, 19 studies were carried out in Caucasians, 7 in Asians
and 2 in other populations. As a result, we conducted a meta-analysis
with 4703 controls and 3452 schizophrenics. The Hardy–Weinberg
equilibrium (HWE) was measured in all the included studies and also in
a pool made of the results from all the studies (combined data; Table 3).
3.2. Meta-analysis
First, we evaluated the interaction of ApoE with schizophrenia in all
the populations of the studies included in this work. We measured the
role of this gene in three models (Table 4; Figs. 3 and 4). In the ﬁrst
model, ε4 vs ε3, the combined ORs and 95% CI showed that ApoE did
not increase signiﬁcantly the risk for schizophrenia [OR 0.95; 95% CI
Table 2
Summary ﬁnding of study association between ApoE gene variant and schizophrenia.
Reference OR (CI 95%) Number of patients (studies) Design Quality evidence (GRADES) Publication bias
Harrington et al. (1995) 2.15 (1.18–3.92) 42 Case–control
Moderate
Undetected
Joober et al. (1996) 1.01 (0.33–3.04) 51 Case–control
Moderate
Undetected
Jonsson et al. (1996) 0.94 (0.51–1.72) 87 Case–control
High
Undetected
Zhu et al. (1996) 1.15 (0.54–2.41) 98 Case–control
Moderate
Undetected
Igata-Yi et al. (1997) 0.44 (0.16–1.20) 54 Case–control
Moderate
Undetected
Kimura et al. (1997) 0.81 (0.44–1.49) 122 Case–control
Moderate
Undetected
Lan et al. (1997) 0.51 (0.20–1.25) 62 Case–control
High
Undetected
Town et al. (1997) 1.05 (0.60–1.83) 63 Case–control
Moderate
Undetected
Arnold et al. (1997) 1.23 (0.69–2.20) 93 Case–control
High
Undetected
Thibaut et al. (1998) 0.81 (0.49–1.33) 134 Case–control
Moderate
Undetected
Sorbi et al. (1998) 1.22 (0.55–2.71) 69 Case–control
Moderate
Undetected
Fernández et al. (1999) 0.94 (0.42–2.08) 40 Case–control
Moderate
Undetected
Chen et al. (1999) 0.48 (0.27–0.87) 237 Case–control
Moderate
Undetected
Thibaut et al. (1999) 0.48 (0.27–0.85) 106 Case–control
Moderate
Undetected
Durany et al. (2000) 1.20 (0.59–2.42) 114 Case–control
Moderate
Undetected
Kimura et al. (2000) 0.89 (0.59–1.35) 333 Case–control
Moderate
Undetected
Martorell et al. (2001) 1.01 (0.73–1.39) 365 Case–control
Moderate
Undetected
Lee et al. (2001) 0.37 (0.11–1.24) 60 Case–control
High
Undetected
Saiz et al. (2002) 1.48 (0.82–2.70) 106 Case–control
High
Undetected
Schurhoff et al. (2003) 1.31 (0.74–2.33) 114 Case–control
Moderate
Undetected
Liu et al. (2003) 1.67 (1.34–2.08) 579 Case–control
Moderate
Undetected
Dean et al. (2003) 1.02 (0.38–2.74) 23 Case–control
Moderate
Undetected
Kampman et al. (2004) 1.36 (0.82–2.24) 94 Case–control
High
Undetected
Moberg et al. (2006) 3.40 (1.15–9.97) 28 Case–control
Moderate
Undetected
Akanji et al. (2009) 1.17 (0.71–1.92) 207 Case–control
Moderate
Undetected
Tovilla-Zárate et al. (2009) 0.20 (0.09–0.44) 60 Case–control
High
Undetected
Kecmanovic et al. (2010) 1.50 (0.74–3.05) 76 Case–control
High
Undetected
Vila-Rodríguez et al. (2011) 1.08 (0.40–2.93) 35 Case–control
Moderate
Undetected
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were observed in the second model (ε4 vs ε2): the combined ORs and
95% CI did not increase the risk for schizophrenia [OR 1.08; 95% CI
(0.92–1.28); p of Egger's test: 0.70; p of Q test: 0.34].Whenwe analyzed
the ﬁnal model (ε4 vs ε3 + ε2), we did not ﬁnd any signiﬁcant associa-
tion either [OR 1.01; 95% CI (0.88–1.16); p of Egger's test: 0.53; p of Q
test: 0.25]. After discarding the studies favoring heterogeneity no asso-
ciation was observed in all models tested (Figs. 5 and 6).
Subsequently, we conducted an analysis by populations. We evalu-
ated the role played by the ApoE gene in Asian schizophrenics (Figs. 7
and 8). The analysis did not show heterogeneity and revealed a statisti-
cal protection in the model ε4 vs ε3. In addition, the combined ORs and95%CI exhibited a decrease in the risk for schizophrenia [OR 0.72; 95%CI
(0.52–0.98); p of Egger's test: 0.12; p of Q test: 0.36], whereas no signif-
icant association was shown in the model ε4 vs ε2 [OR 1.11; 95% CI
(0.87–1.42); p of Egger's test: 0.54; p of Q test: 0.48]. Finally, a decrease
in the risk for schizophrenia was also observed in the model ε4 vs
ε3 + ε2 [OR 0.66; 95% CI (0.50–0.88); p of Egger's test: 0.25; p of Q
test: 0.36] (Figs. 9 and 10). Our results as a whole suggest that ApoE
ε3 could be a protective factor in the Asian population.
With regard to the Caucasian population, 19 studies were evaluated
which did not present heterogeneity (Table 4). Combined ORs and 95%
CI yielded no association between ApoE and schizophrenia in this pop-
ulation after using the following the models: ε4 vs ε3 [OR 1.14; 95% CI
Fig. 1. Flow-chart illustrating the search strategy and inclusion/exclusion criteria used in the meta-analysis and systematic review.
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95% CI (0.91–1.39); p of Egger's test: 0.20; p of Q test: 0.64] and ε4 vs
ε3 + ε2 [OR 1.13; 95% CI (0.96–1.33); p of Egger's test: 0.48; p of Q
test: 0.21] (Figs. 11 and 12).
To expand our results further, we analyzed the Caucasian population
in American and Europeanwhites. Whenwe explored the ApoE gene in
onlywhite Americanswe did not obtain any signiﬁcant association in all
themodels proposed: ε4 vs ε2 [OR 0.84; 95% CI (0.51–1.38); p of Egger's
test: 0.17; p of Q test: 0.57], ε4 vs ε3 [OR 1.25; 95% CI (0.86–1.82); p of
Egger's test: 0.48; p of Q test: 0.24] and ε4 vs ε3 + ε2 [OR 1.17; 95% CI
(0.81–1.69); p of Egger's test: 0.45; p of Q test: 0.36]. With regard toFig. 2. Distribution of association studies on ApoE and schizophrEuropean whites, the analysis showed the same negative outcomes:
ε4 vs ε2 [OR 1.19; 95% CI (0.94–1.51); p of Egger's test: 0.14; p of Q
test: 0.63], ε4 vs ε3 [OR 1.12; 95% CI (0.92–1.37); p of Egger's test:
0.40; p of Q test: 0.10] and ε4 vs ε3 + ε2 [OR 1.13; 95% CI (0.93–
1.37); p of Egger's test: 0.39; p of Q test: 0.11].
4. Discussion
ApoE is an essential enzyme in the modulation of cholesterol and
phospholipid transport among cells, but even more important is the
fact that this protein is produced by astrocytes where it plays a vitalenia published in PubMed by year (www.gopubmed.com).
Table 3
Descriptive characteristics of ApoE gene variants in association studies.
Reference Location Scale Males/females Number Mean age (range) Alleles p for HWE
Cases Controls Cases Controls Cases Controls Cases
ε4/ε3/ε2
Controls
ε4/ε3/ε2
Cases Controls
Europeans (Caucasians)
Harrington et al. (1995) UK Unspeciﬁed 18/24 70/61 42 131 65 (19–95) 55 (19–98) 22/57/5 37/203/22 0.92 0.11
Jonsson et al. (1996) Sweden DSM-IIIR 56/31 34/23 87 57 46 (20–90) 38 (29–55) 32/133/9 22/81/11 0.92 0.70
Zhu et al. (1996) Germany DSM-IV – – 98 98 – – 18/40/40 16/40/42 0.16 0.22
Sorbi et al. (1998) Italy DSM-IIIR 47/22 34/87 69 121 – 60 (27–81) 11/118/9 16/215/11 0.11 0.07
Thibaut et al. (1998) France DSM-IIIR 90/44 60/43 134 103 42 44 39/209/17 36/157/13 0.00⁎ 0.00⁎
Thibaut et al. (1999) France DSM-IIIR 77/22 58/40 106 98 38 (22–60) 41 (22–60) 28/168/16 33/93/13 0.17 0.13
Durany et al. (2000) Spain DSM-IV – – 114 94 – 24/45/45 16/40/32 0.06 0.54
Martorell et al. (2001) Spain ICD-9 222/143 366/218 365 548 56 (19–90) 52 (19–97) 68/615/41 108/995/65 0.80 0.17
Saiz et al. (2002) Spain DSM-IV – – 106 250 – – 19/186/7 31/442/27 0.31 0.97
Schurhoff et al. (2003) France DSM-IV 56/58 54/37 114 91 – 50 35/172/21 22/149/11 0.41 0.60
Kampman et al. (2004) Finland DSM-IV – – 94 98 – – 43/136/9 35/147/14 0.18 0.17
Kecmanovic et al. (2010) Serbia DSM-IV 33/43 42/40 76 82 – – 20/122/10 15/135/14 0.06 0.78
Pooled 1405 1771 359/2001/229 387/2697/275 0.60 0.54
Americans (Caucasians)
Joober et al. (1996) Canada Unspeciﬁed – – 51 35 41 65 8/20/23 7/18/20 0.31 0.39
Town et al. (1997) USA DSM-IIIR – – 63 301 42 71 18/96/12 82/486/34 0.18 0.09
Arnold et al. (1997) USA DSM-IIIR 54/46 50/56 93 106 42 28 29/131/22 25/136/27 0.00⁎ 0.06
Fernández et al. (1999) USA DSM-IIIR – – 40 57 15 15 12/56/12 18/86/10 0.00⁎ 0.41
Vila-Rodríguez et al. (2011) Canada DSM-IV 26/9 26/9 35 35 – 44 9/49/8 9/53/9 0.91 0.52
Moberg et al. (2006) USA DSM-IV 14/14 15/11 28 26 29 26 17/29/18 5/37/10 0.41 0.45
Pooled 310 560 93/381/95 146/816/110 0.33 0.52
Others (Caucasians)
Dean et al. (2003) Australia DSM-IV 15/8 30/17 23 47 42 55 7/38/1 14/73/7 0.38 0.38
Chinese (Asians)
Lan et al. (1997) China DSM-IV 22/40 36/27 62 63 35 (19–55) 35 (24–48) 8/109/7 15/102/9 0.58 0.98
Chen et al. (1999) China DSM-IV – – 237 117 – – 23/419/32 26/207/41 0.04⁎ 0.65
Liu et al. (2003) China DSM-IV 260/319 1070/458 579 1528 – – 142/909/107 236/2586/234 0.15 0.22
Pooled 878 1708 173/1437/146 277/2895/284 0.67 0.63
Others (Asians)
Igata-Yi et al. (1997) Japan DSM-IV 15/39 17/16 54 33 36 (12–87) 53 (24–88) 8/92/8 10/52/4 0.00⁎ 0.17
Kimura et al. (1997) Japan DSM-IIIR 60/62 45/81 122 126 47 42 21/209/14 26/215/11 0.19 0.92
Kimura et al. (2000) Japan DSM-IV 167/166 57/134 333 191 40 40 65/568/33 41/323/18 0.75 0.33
Lee et al. (2001) Korea DSM-IV 39/21 30/30 60 60 32 35 4/113/3 10/97/13 0.78 0.24
Pooled 569 410 98/982/58 87/687/46 0.67 0.72
Others
Akanji et al. (2009) Kuwait DSM-IV – – 207 165 – – 42/185/187 29/151/150 0.70 0.29
Tovilla-Zárate et al. (2009) Mexico DSM-IV 60 42 33 (18–60) 81 (60–97) 8/106/6 43/117/4 0.58 0.41
Pooled 267 207 50/291/193 72/268/154 0.11 0.17
All Pooled 3452 4703 780/5130/722 983/7436/876 0.70 0.28
–, no obtainable data.
⁎ p signiﬁcant value.
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ly, this issue drew the interest of Harrington et al. (1995) who analyzed
the participation of the ApoE gene in the pathology of schizophrenia.
Since then, several researchers have focused their attention on the in-
teraction of allele ε4 as major risk factor in schizophrenics, though the
results of the studies have been contrasting (Dean et al., 2003; Kimura
et al., 2000; Tovilla-Zárate et al., 2009). Therefore, our aim was to
evaluate this association in a systematic review and meta-analysis to
determine the role of this gene using available published data.
Our analysis showed a relationship when we analyzed the ApoE
gene in Asian populations using models ε4 vs ε3 [OR 0.72; 95% CI
(0.52–0.98)] and ε4 vs ε3 + ε2 [OR 0.66; 95% CI (0.50–0.88)]. The
obtained outcomes suggest a possible protective effect of allele ε3 to
present a schizophrenic disorder. In this sense, some studies have deter-
mined that the allelic distribution of ApoE gene depends on the ethnic
origin of the sample (Seixas et al., 1999). For example, in the study of
Corbo and Scacchi (1999), the authors describe that the allele distribu-
tion has a strongly marked difference between the Chinese population
and American or European whites. As a result, when we analyzed the
Caucasian population, we divided it in two groups Americans and
Europeans, but we did not ﬁnd any association with schizophrenia.We recommend to take these results with caution because it is neces-
sary to make further analyses using larger samples and to perform an
ancestral analysis. Moreover, we have observed that most of the popu-
lation of schizophrenic patients analyzed is male; this result is interest-
ing given that gender differences have been reported to inﬂuence
schizophrenia. For example, Schurhoff et al. (2003) reported an associ-
ation between ApoE ε2ε3 genotypes and male schizophrenic patients.
They also mentioned that ApoE ε2 may have a protective effect only in
women. Therefore, the ApoE variant may modulate its phenotypic
expression in a sex-dependent manner (Martorell et al., 2001). In
order to have conclusive results, we suggest that more studies must
be undertaken to investigate this association.
This evidencemust be takenwith caution. First, not only theApoE al-
lele distribution is affected by the ethnic origin of the sample, but also it
has been proposed that the ethnic origin may inﬂuence the expression
of this gene. On the other hand, there is the possibility that the interac-
tion of a hypothetic genemay be playing a role in the distribution of the
ApoE gene and its effects on schizophrenia. Furthermore, ApoE could be
a predisposing gene,whichmay exert a small effect on the development
of schizophrenia in some populations. It is possible that previous studies
reporting a null association could be due to the small size of the sample
Table 4
Meta-analysis of case–control studies on ApoE gene variants in patients with schizophrenia.
Models analysis Model effects p value of Q test p value of Egger's test
Random
OR (CI 95%)
Fixed
OR (CI 95%)
All populations
ε4 vs ε3 With heterogeneity 0.98 (0.81–1.20) 1.10 (0.99–1.22) b0.0001 0.46
Without heterogeneity 0.95 (0.81–1.10) 0.95 (0.84–1.08) 0.13 0.20
ε4 vs ε2 With heterogeneity
Without heterogeneity 1.08 (0.92–1.28) 1.10 (0.94–1.28) 0.34 0.70
ε4 vs ε3 + ε2 With heterogeneity 1.10 (0.99–1.22) 0.99 (0.82–1.19) b0.0001 0.46
Without heterogeneity 1.01 (0.88–1.16) 1.01 (0.89–1.14) 0.25 0.53
Caucasian population
ε4 vs ε3 With heterogeneity
Without heterogeneity 1.14 (0.96–1.35) 1.12 (0.97–1.29) 0.14 0.67
ε4 vs ε2 With heterogeneity
Without heterogeneity 1.13 (0.91–1.39) 1.13 (0.91–1.39) 0.64 0.20
ε4 vs ε3 + ε2 With heterogeneity
Without heterogeneity 1.13 (0.96–1.33) 1.12 (0.97–1.28) 0.21 0.48
Asian population
ε4 vs ε3 With heterogeneity 0.70 (0.41–1.18) 1.15 (0.97–1.36) b0.0001 0.12
Without heterogeneity 0.72 (0.52–0.98) 0.73 (0.54–0.98) 0.36 0.12
ε4 vs ε2 With heterogeneity
Without heterogeneity 1.11 (0.87–1.42) 1.11 (0.87–1.42) 0.48 0.54
ε4 vs ε3 + ε2 With heterogeneity 0.72 (0.44–1.18) 1.15 (0.97–1.36) b0.0001 0.22
Without heterogeneity 0.66 (0.50–0.88) 0.67 (0.52–0.88) 0.36 0.25
360 T.B. González-Castro et al. / Schizophrenia Research 169 (2015) 355–368studied. This assumption must be considered because, in the present
meta-analysis, 16 of the 28 studies included less than 200 subjects
(Table 3).Fig. 3. Odds ratios and forest plots of ApoE in overall studies with heterogWe want to emphasize the existence of 3 previous meta-analyses
(Schurhoff et al., 2003; Tovilla-Zárate et al., 2008; Xu et al., 2006) of
the ApoE gene, but 2 of them did not focus their analyses in assessingeneity, using the following models: A) ε4 vs ε3 and B) ε4 vs ε3 + ε2.
Fig. 4. Egger's funnel plots indicating publication bias in all the studies on schizophrenics and ApoE, with heterogeneity, using the following models: A) ε4 vs ε3 and B) ε4 vs ε3 + ε2.
361T.B. González-Castro et al. / Schizophrenia Research 169 (2015) 355–368the interaction by population.Hence further studieswith larger samples
as the present one are required to get more conclusive results. In addi-
tion, these previous meta-analyses evaluated only the interaction of ε4
carriers vs non-carriers and not of all the alleles tested independently;
this is the strength of our present work. On other hand, although ApoE
was not found as risk factor in schizophrenics compared to controls,
we still consider the possibility that ApoE may affect in some way the
expression of the disease.
Our data present several limitations. This sample is not large enough,
and it is possible that the statistical power is not enough to detect small
effects of the ApoE gene, so no deﬁnitive conclusions can be drawn. On
the other hand, to ensure that our meta-analysis excluded poorly de-
signed studies, we selected only published reports. Also, the period of
publication is short. In consequence, it is necessary to evaluate this in-
formation with new available data. Alternatively, we did not analyze
endophenotypes that could be involved in schizophrenics; we believe
unlikely that diagnostic features in the classiﬁcation of schizophrenics
can represent a serious problem. Finally, because many data were in-
complete and we could not obtain the information from the authors,
we did not perform sub-analyses with potentially confounder factors
such as gender, age and lifestyle, among others.
In conclusion, our ﬁndings suggest that allele ε3 may have a protec-
tive association to present schizophrenia in Asian populations. Howev-
er, it is probable that the ApoE gene exerts a small effect. Therefore, it
is necessary to carry out further studieswith a larger number of patients
and new data to gain a better understanding into the role of the ApoE
gene in the development of schizophrenia.Role of funding source
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Fig. 9. Odds ratios and forest plots of ApoE in Asian population studies, without heterogeneity, using the following models: A) ε4 vs ε3; B) ε4 vs ε2 and C) ε4 vs ε3 + ε2.
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Fig. 10. Egger's funnel plots indicating publication bias in Asian population studies, without heterogeneity, using the following models: A) ε4 vs ε3; B) ε4 vs ε2 and C) ε4 vs ε3 + ε2.
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Fig. 11. Odds ratios and forest plots of ApoE in Caucasian population studies, without heterogeneity, using the following models: A) ε4 vs ε3; B) ε4 vs ε2 and C) ε4 vs ε3 + ε2.
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Fig. 12. Egger's funnel plots indicating publication bias in Caucasian population studies, without heterogeneity, using the following models: A) ε4 vs ε3; B) ε4 vs ε2 and C) ε4 vs ε3 + ε2.
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